CINECA IRIS Institutional Research Information System

ARTUSI, Carlo Alberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.984
EU - Europa 2.457
AS - Asia 1.646
SA - Sud America 81
OC - Oceania 61
AF - Africa 53
Continente sconosciuto - Info sul continente non disponibili 9
Totale 9.291
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.894
IT - Italia 675
CN - Cina 662
SG - Singapore 463
IE - Irlanda 340
SE - Svezia 316
DE - Germania 202
FR - Francia 159
GB - Regno Unito 135
FI - Finlandia 119
JP - Giappone 98
ES - Italia 85
VN - Vietnam 76
NL - Olanda 73
CA - Canada 70
IN - India 66
KR - Corea 61
BE - Belgio 58
AU - Australia 54
PL - Polonia 54
BR - Brasile 49
AT - Austria 47
TR - Turchia 47
ID - Indonesia 38
UA - Ucraina 38
HK - Hong Kong 33
TW - Taiwan 33
CH - Svizzera 28
PT - Portogallo 22
SN - Senegal 19
RO - Romania 18
MX - Messico 16
GR - Grecia 14
IR - Iran 14
RU - Federazione Russa 13
DK - Danimarca 12
IL - Israele 11
BG - Bulgaria 10
EG - Egitto 10
CL - Cile 9
CZ - Repubblica Ceca 9
UZ - Uzbekistan 8
CO - Colombia 7
EU - Europa 7
NZ - Nuova Zelanda 7
CI - Costa d'Avorio 6
EC - Ecuador 6
AR - Argentina 5
IS - Islanda 5
NO - Norvegia 5
PE - Perù 5
PH - Filippine 5
TH - Thailandia 5
TN - Tunisia 5
ZA - Sudafrica 5
SK - Slovacchia (Repubblica Slovacca) 4
HU - Ungheria 3
KZ - Kazakistan 3
MU - Mauritius 3
MY - Malesia 3
NG - Nigeria 3
SA - Arabia Saudita 3
AE - Emirati Arabi Uniti 2
BN - Brunei Darussalam 2
BY - Bielorussia 2
CY - Cipro 2
EE - Estonia 2
HN - Honduras 2
LT - Lituania 2
NP - Nepal 2
PK - Pakistan 2
SI - Slovenia 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AF - Afghanistan, Repubblica islamica di 1
DZ - Algeria 1
GH - Ghana 1
HR - Croazia 1
JM - Giamaica 1
KW - Kuwait 1
LB - Libano 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
MM - Myanmar 1
MO - Macao, regione amministrativa speciale della Cina 1
RS - Serbia 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
YE - Yemen 1
Totale 9.291
Salva come PNG Salva come JPEG
Città #
Chandler 695
Santa Clara 439
Singapore 386
Dublin 338
Beijing 283
Fairfield 235
Ashburn 208
Torino 181
Nyköping 168
Houston 148
Redwood City 135
Wilmington 133
Ann Arbor 131
Columbus 111
Medford 108
Seattle 108
Princeton 103
Woodbridge 102
Turin 89
Cambridge 88
Fremont 86
Villeurbanne 81
Dearborn 70
Jacksonville 66
Helsinki 59
Dong Ket 53
Milan 45
Boston 44
Guangzhou 44
Hangzhou 43
Vienna 43
Pisa 42
New York 38
Warsaw 34
Jakarta 33
Shanghai 28
Seoul 27
Madrid 26
Boardman 25
Brussels 24
Munich 23
Ottawa 22
Hong Kong 20
Istanbul 20
Rome 20
Taipei 20
Chengdu 19
Norwalk 18
San Diego 17
Hebei 16
London 15
Nanjing 15
Washington 15
Los Angeles 13
Tokyo 13
Toronto 13
Jinan 12
Hefei 11
Changsha 10
Chicago 10
Duncan 9
Oxford 9
Paris 9
Amsterdam 8
Düsseldorf 8
Falkenstein 8
Falls Church 8
Genoa 8
Pune 8
Renton 8
Sydney 8
Wuhan 8
Barcelona 7
Bologna 7
Delhi 7
Edinburgh 7
Kunming 7
Melbourne 7
Minneapolis 7
Polska 7
Santiago 7
Zhengzhou 7
Abidjan 6
Aracaju 6
Berlin 6
Cincinnati 6
Gazi 6
Groslay 6
Hamburg 6
Nashville 6
Pamplona 6
Rio de Janeiro 6
Riverton 6
Rochester 6
Tejupilco de Hidalgo 6
Trento 6
Valencia 6
Zurich 6
Antwerp 5
Bethesda 5
Totale 5.697
Salva come PNG Salva come JPEG
Nome #
Parkinson's disease progression at 30 years: a study of subthalamic deep brain-stimulated patients. 752
Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience 434
Transient effects of 80 Hz stimulation on gait in STN DBS treated PD patients: a 15 months follow-up study. 349
Subthalamic deep brain stimulation: clinical and neuropsychological outcomes in mild cognitive impaired parkinsonian patients. 336
Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis 332
Medical therapy and subthalamic deep brain stimulation in advanced Parkinson's disease: a different long-term outcome? 277
80 Hz versus 130 Hz subthalamic nucleus deep brain stimulation: effects on involuntary movements. 270
Prospective assessment of peripheral neuropathy in Duodopa-treated parkinsonian patients 264
Subthalamic nucleus deep brain stimulation outcome in young onset Parkinson's disease: a role for age at disease onset? 253
Natalizumab-related progressive multifocal leukoencephalopathy in multiple sclerosis: Findings from an Italian independent registry 185
Natalizumab in Multiple Sclerosis: Long-Term Management 142
Telemedicine for management of patients with amyotrophic lateral sclerosis through COVID-19 tail 135
Cytomegalovirus Reactivation During Alemtuzumab Treatment for Multiple Sclerosis: A Case Report 131
Neurological comorbidity and severity of COVID-19 123
Telemedicine and the challenge of epilepsy management at the time of COVID-19 pandemic 121
Safety and efficacy of tolcapone in Parkinson’s disease: systematic review 114
Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea 103
3 years comparison between duodopa and Deep Brain Stimulation 90
Beyond Nine Years of Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson’s Disease 88
Cardiovascular autonomic neuropathy and falls in Parkinson disease: a prospective cohort study 88
Benign versus malignant Parkinson disease: the unexpected silver lining of motor complications 88
Botulinum toxin for Pisa syndrome: An MRI-, ultrasound- and electromyography-guided pilot study 86
Parkinsonian traits in amyotrophic lateral sclerosis (ALS): a prospective population-based study 83
Pisa syndrome in Parkinson's disease is associated with specific cognitive alterations 82
Earlier versus later subthalamic deep brain stimulation in Parkinson's disease 80
Deep brain stimulation in uncommon tremor disorders: indications, targets, and programming 79
Deep brain stimulation fine-tuning in Parkinson's disease: Short pulse width effect on speech 79
Atypical Presentation of Progressive Multifocal Leukoencephalopathy in a Natalizumab-treated Patient 78
The dominant subthalamic nucleus: A gait analysis study 78
How to treat patients after natalizumab discontinuation: the TY-STOP 2 study, an Italian, prospective and multicenter study 77
Cytomegalovirus reactivation during alemtuzumab treatment in a patient with multiple sclerosis 75
Complex therapies for advanced Parkinson’s disease: what is the role of doctor-patient communication? 74
Long-term follow-up of ultrasound-guided botulinum toxin-A injections for sialorrhea in neurological dysphagia 73
Long-term effect of levodopa-carbidopa intestinal gel on axial signs in Parkinson’s disease 73
Should We Consider Deep Brain Stimulation Discontinuation in Late-Stage Parkinson’s Disease? 73
Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab 72
Continuous intraduodenal L-dopa/carbidopa gel infusion improves nocturnal sleep in advanced Parkinson’s disease 71
Orthostatic hypotension in Parkinson disease: Impact on health care utilization 71
The still under-investigated role of cognitive deficits in PML diagnosis 71
Botulinum Toxin A for Treatment of Sialorrhea in neurologic diseases: 2-year Prospective Study 69
Changing the Side of Pisa Syndrome: A Case of Over-Recovery with Botulinum Toxin 69
COVID-19 and Parkinson's Disease: What We Know So Far? 69
Anxiety, depression, and worries in advanced Parkinson disease during COVID-19 pandemic 68
Time to onset and duration of botulinum toxin efficacy in movement disorders 68
Clinical efficacy of different stimulation frequencies on dyskinesias and dystonias in subthalamic nucleus deep brain stimulation patients with parkinson's disease 67
Beyond 10 years of levodopa intestinal infusion experience: Analysis of mortality and its predictors 67
Effects of 80 Hz stimulation on gait in STN-DBS treated PD patients 66
Levodopa/Carbidopa Intestinal Gel Long-Term Outcome in Parkinson's Disease: Focus on Dyskinesia 66
Ultrasound-guided botulinum toxin-A for sialorrhea: a 2-year prospective study 65
Early diagnosis of progressive multifocal leucoencephalopathy: Longitudinal lesion evolution 65
Effects of intestinal Levodopa infusion on freezing of gait in Parkinson disease 65
Motor and non-motor outcomes of subthalamic deep brain stimulation in a case of juvenile PARK-PINK1 65
Telemedicine in Neurological Disorders: Opportunities and Challenges 63
Parkinsonism–hyperpyrexia syndrome and deep brain stimulation 63
Differential response to pallidal deep brain stimulation among monogenic dystonias: Systematic review and meta-analysis 62
A new index to assess turning quality and postural stability in patients with Parkinson's disease 62
Association between sleep disorders and cognitive dysfunctions in non-demented patients with advanced Parkinson’s disease 62
Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease 62
Home monitoring of motor fluctuations in Parkinson’s disease patients 61
COVID-19 in Parkinson's disease: Report on prevalence and outcome 60
Implementation of Mobile Health Technologies in Clinical Trials of Movement Disorders: Underutilized Potential 60
Friedreich's ataxia patients and caregivers information seeking behaviour 59
Association of Subthalamic Deep Brain Stimulation With Motor, Functional, and Pharmacologic Outcomes in Patients With Monogenic Parkinson Disease: A Systematic Review and Meta-analysis 59
Ventral Tegmental Area Disconnection Contributes Two Years Early to Correctly Classify Patients Converted to Alzheimer's Disease: Implications for Treatment 59
Deep brain stimulation outcomes in the malignant end of Parkinson's disease spectrum 59
Low frequency subthalamic stimulation and event-related potentials in Parkinson disease 58
Tuning Deep Brain Stimulation related depression by frequency modulation: a case report 57
Peripheral neuropathy in Parkinson’s disease patients treated with duodenal levodopa/carbidopa infusion: A clinical and electrophysiological follow-up study 56
Onset of Covid-19 with impaired consciousness and ataxia: a case report 56
Video analysis of long-term effects of levodopa-carbidopa intestinal gel on gait and posture in advanced Parkinson’s disease 55
Gene Therapy in Movement Disorders: A Systematic Review of Ongoing and Completed Clinical Trials 55
Early reversible leukoencephalopathy and unilateral sixth cranial nerve palsy in mild COVID-19 infection 55
G325R GBA mutation in Parkinson's disease: Disease course and long-term DBS outcome 50
Digital work engagement among Italian neurologists 50
Levodopa-Induced Dyskinesias and Dyskinesias-Reduced-Self-Awareness in Parkinson’s Disease: A Neurocognitive Approach 49
To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy 49
Neurological comorbidities and COVID-19-related case fatality: A cohort study 49
Focal seizures with impaired awareness as long-term neurological complication of COVID-19: a case report 49
Parkinson's clinical features after 30 years of disease: A study from patients treated by subthalamic nucleus stimulation 47
Prevalence and burden of dysautonomia in advanced Parkinson's disease 47
Deep brain stimulation for atypical parkinsonism: A systematic review on efficacy and safety 46
Telemedicine in Parkinson's Disease: How to Ensure Patient Needs and Continuity of Care at the Time of COVID-19 Pandemic 45
Deep Brain Stimulation Selection Criteria for Parkinson's Disease: Time to Go beyond CAPSIT-PD 45
Effect of subthalamic deep brain stimulation on posture in Parkinson's disease: A blind computerized analysis 44
Postural Abnormalities in Parkinson's Disease: An Epidemiological and Clinical Multicenter Study 44
Improving the care of Rebif® treated Multiple Sclerosis patients: the "MSdialog" experience 43
Prospective assessment of peripheral neuropathy in duodopa treated patients 40
Long-term duodenal levodopa infusion in Parkinson's disease: a 3-year motor and cognitive follow-up study 40
Subthalamic deep brain stimulation and trunk posture in Parkinson's disease 39
Levodopa-Induced Neuropathy: A Systematic Review 37
Effects of dopaminergic therapy on sleep quality in fluctuating Parkinson’s disease patients 36
Levodopa-Induced Dyskinesias and Dyskinesias-Reduced-Self-Awareness in Parkinson’s Disease: A Neurocognitive Approach 35
Are patients with GBA-Parkinson disease good candidates for deep brain stimulation? A longitudinal multicentric study on a large Italian cohort 32
Subthalamic deep brain stimulation and levodopa in Parkinson’s disease: a meta-analysis of combined effects 32
Integration of technology-based outcome measures in clinical trials of Parkinson and other neurodegenerative diseases 32
Burden of caregiving for cardiovascular dysautonomia in Parkinson's disease 31
SARS-CoV-2 vaccination, Parkinson's disease, and other movement disorders: case series and short literature review 30
Postural abnormalities in Asian and Caucasian Parkinson's disease patients: A multicenter study 30
Efficacy of rituximab in anti-myelin-associated glycoprotein demyelinating polyneuropathy: Clinical, hematological and neurophysiological correlations during 2 years of follow-up 29
Gait and axial postural abnormalities correlations in Parkinson's disease: A multicenter quantitative study 28
Totale 9.230
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.252
article - articoli 0
book - libri 0
conference - conferenze 3.977
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.229
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020588 0 0 0 0 0 101 100 87 79 79 73 69
2020/20211.090 63 79 59 137 82 108 46 79 98 87 85 167
2021/20221.279 81 44 52 98 75 62 64 61 53 94 317 278
2022/20231.927 203 196 52 222 166 463 111 114 165 71 105 59
2023/2024957 114 157 44 49 53 137 35 84 4 83 59 138
2024/20251.473 53 176 77 257 698 212 0 0 0 0 0 0
Totale 9.601